Memento Medicines

Generating profile summary — check back in a moment.

Highlights

Total Raised

—

1 rounds

Latest Round

$93

Jun 19, 2026

Stage

deep-tech

Employees

Headquarters

News Coverage

1 articles

Last: Today

Talent Signals

1 moves

SEC Filings

—

Backers

Avego BioScience Capital

Forbion

RA Capital Management

Samsara BioCapital

Sanofi Ventures

Funding History

$93

2026

Series A

SEC Form D Editorial

Jun 19, 2026

$93 millionSeries A · Editorial

Investors: Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures, Samsara BioCapital

Memento Medicines closed a $93M Series A to develop MMT-205, a bispecific antibody targeting Tie2 activation and VEGF inhibition for nAMD and DME, with potential milestone payments up to $1.08B from licensed partners MabTics and Curacle.

View article →

News Coverage 1

DeepToday

Memento launches $93M bispecific bet against retinal disease standard

Memento Medicines raised $93M to develop MMT-205, a dual-mechanism antibody challenging anti-VEGF monotherapy dominance in nAMD and DME markets worth billions annually.

Talent 1

Naveen Daryani

appointmentCEOJun 19, 2026

Source →

Similar Companies 6

Nalu Medical Sievert Larsen & Associates Sera Medicines BayerPublic Regeneron BioAge Labs